Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1-20 (Cancelled)

21 (Currently amended). A compound of formula AXB useful ~~for use~~ in inducing necrosis in vascular tissue of a tumor in ~~an animal~~ a mammal, said compound containing (a) a first moiety, A, which is a cis-stilbene moiety of formula II



~~Wherein~~ wherein R1, R2 and R3 are each independently H, optionally substituted alkoxy, optionally substituted alkyl or halogen

R4 is hydrogen or cyano

R5, R6 and R7 are each independently H, hydroxy, optionally substituted alkyl, halogen, amino, alkylamino, dialkylamino, cyano, nitro, carboxyl, alkanoyl, alkoxycarbonyl, alkoxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, di alkylaminocarbonylamino, alkylcarbonylamino, alkylsulphonyl, aminosulphonyl, alkylaminosulphonyl, dialkylaminosulphonyl, alkylsulphonylamino, aminosulphonylamino, alkylaminosulphonylamino, dialkylaminosulphonylamino, mercapto, alkylsulphanyl,or alkylsulphinyl,
with the proviso that at least to of R1, R2 and R3 must be optionally substituted alkoxy,
and (b) a second moiety, B, which is an inhibitor of nitric oxide synthase ~~the formation or action of nitric acid~~, said first and second moieties being coupled in the compound by a linker bond, atom or group X such that the compound has an increased activity in inducing necrosis in said vascular tissue as compared with a compound containing said first moiety without the second moiety.

22 (Canceled)

23 (Currently amended). The compound according to claim ~~22~~ 21, wherein the compound is a hydrate, or a pharmaceutically acceptable salt thereof ~~or a prodrug~~.

24 (Currently amended). The compound according to claim ~~22~~ 21, wherein the first and second moieties are coupled through a linker ~~bond, atom or~~ group.

25 (Currently amended) The compound according to claim ~~22~~ 24, in which the first and second moieties are coupled through a linker group selected from the group consisting of an optionally substituted methylene chain, and $-(CH_2)_m-Y-(CH_2)_n-$ wherein Y is selected from -O-, -S-, SO_2-, NH-, Nalkyl-, -CO-, -OC(O)-, -NHC(O)-, -N(alkyl)C(O)-, -NHC(O)NH-, NalkylC(O)NH-NalkylC(O)Nalkyl-, $-NHSO_2-$, $NalkylSO_2-$, $NHSO_2NH-$, $NalkylSO_2NH-$, $NalkylSO_2Nalkyl-$ and -OC(O)O-, m is 0-3 and n is 0-3.

26 (Currently amended) The compound according to claim ~~22~~ 21, in which the second moiety is selected from the group consisting of an amino acid inhibitor of nitric oxide synthase, a ~~tiocitrulline~~ thiocitrulline derivative, an S-alkylisothiourea derivative and a 2-aminopyridine

derivative.

Claim 27 (Currently amended) The compound according to claim ~~22~~ 21, wherein the second moiety is a group -C(O)CH(NH_2)-CH_2)p-NHC(NH)Z wherein p is 1-5 and Z is alkyl, alkylamino, dialkylamino, nitroamino, hydrazino or alkylthio, or a group -NHCH(CO_2R10)-(CH_2)p-NHC(NH)Z and R10 is hydrogen or alkyl.

Claim 28 (Currently amended) The compound according to claim ~~22~~ 21, wherein the second moiety is a group -C(O)CH(NH_2)-CH_2p-NHC(S)NH_2 or a group -NHCH(CO_2R10)-(CH_2)p-NHC(S)NH_2.

Claim 29 (Currently amended) The compound according to claim ~~22~~ 21, wherein the second moiety is -(CH_2)p-SC(NH)NH_2.

Claim 30 (Currently amended) The compound according to claim ~~22~~ 21, wherein the second moiety is 4-methyl-2-pyridinylamino.

Claim 31 (Currently amended) The compound according to claim ~~22~~ 21, wherein the compound is



wherein B is the second moiety; X is a linker bond, atom or group; and R8 is alkyl, amino, hydroxy, alkoxy or halogen.

Claim 32 (Previously submitted) The compound according to claim 31, wherein X is -O- or -NH- and B is a group -C(O)CH(NH_2)-(CH_2)p-NHC(NH)Z, wherein p is 1-5 and Z is alkyl, alkylamino, dialkylamino, nitroamino, hydrazino or alkylthio or a group -NHCH(CO_2R10)-CH_2)p-NHC(NH)Z and wherein R10 is hydrogen or alkyl.

Claim 33 (Previously submitted) The compound according to claim 32, wherein the compound is



wherein

R9 is alkyl, alkoxy or halogen

X_1 is O or NH

B_1 is a group -C(O)CH(NH_2)p-NHC(NH)Z wherein p is 1-5 and Z is alkyl, alkylamino, dialkylamino, nitroamino, hydrazino or alkylthio.

34 (Currently amended) The compound according to claim ~~22~~ 21, wherein the compound is

selected from the group consisting of
(Z)-1-(4-~~Methoxy~~ methoxy-3-N^G-nitroarginyloxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene
(Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxycarbonyl]N^G- nitroarginine methyl ester;
(Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxycarbonyl]N^G- nitroarginine; and
(Z)-N-[2-methyl-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxycarbonyl]N^G- nitroarginine methyl ester.

35 (Currently amended) The compound according to claim ~~22~~ 21, wherein the first and second moieties are coupled through a linker bond.

36 (Currently amended). A method for inducing necrosis in vasculature of a tumor in ~~an animal~~ a mammal, comprising administering to the animal the compound of claim 34 in an amount effective for said inducing.

37 (Currently amended). A method for inducing necrosis in vasculature of a tumor in ~~an animal~~ a mammal , comprising administering to the animal the compound of claim ~~22~~ 21 in an amount effective for said inducing.

38 (Currently amended). A method for inducing necrosis in vasculature of a tumor in an animal, comprising administering to the animal the compound of claim 24 in an amount effective for said inducing.

39 (Currently amended). A method for inducing necrosis in vasculature of a tumor in ~~an animal~~ a mammal, comprising administering to the ~~animal~~ mammal the compound of claim 27 in an amount effective for said inducing.

40 (Currently amended). A method for inducing necrosis in vasculature of a tumor in ~~an animal~~ a mammal animal, comprising administering to the animal the compound of claim 31 in an amount effective for said inducing.